Taken together, Xanthoxylin demonstrates potential as a therapeutic agent by modulating the NF-κB and Nrf2 pathways and improving survival rates through a reduction in TNF-α and IL-6 levels in ARDS conditions. This evidence concerns the gene NFE2L2 and acute respiratory distress syndrome.